Spots Global Cancer Trial Database for lutetium lu 177 dotatate
Every month we try and update this database with for lutetium lu 177 dotatate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer | NCT04529044 | Anatomic Stage ... Metastatic Brea... Prognostic Stag... Recurrent Breas... | Lutetium Lu 177... | 18 Years - 100 Years | OHSU Knight Cancer Institute | |
| Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors | NCT04234568 | Metastatic Dige... Metastatic Neur... | Biospecimen Col... Computed Tomogr... Lutetium Lu 177... Magnetic Resona... Triapine | 18 Years - | National Cancer Institute (NCI) | |
| Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy | NCT04082520 | Grade 1 Meningi... Grade 2 Meningi... Grade 3 Meningi... Recurrent Menin... Unresectable Me... | Gallium Ga 68-D... Lutetium Lu 177... Magnetic Resona... Positron Emissi... Questionnaire A... Computed Tomogr... Biospecimen Col... Single Photon E... | 18 Years - | Mayo Clinic | |
| Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors | NCT04750954 | Neuroendocrine ... | Biospecimen Col... Computed Tomogr... Lutetium Lu 177... Magnetic Resona... Peposertib | 18 Years - | National Cancer Institute (NCI) | |
| Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors | NCT05247905 | Metastatic Panc... Unresectable Pa... | Lutetium Lu 177... Capecitabine Temozolomide Quality-of-Life... Questionnaire A... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy | NCT04082520 | Grade 1 Meningi... Grade 2 Meningi... Grade 3 Meningi... Recurrent Menin... Unresectable Me... | Gallium Ga 68-D... Lutetium Lu 177... Magnetic Resona... Positron Emissi... Questionnaire A... Computed Tomogr... Biospecimen Col... Single Photon E... | 18 Years - | Mayo Clinic | |
| Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors | NCT05724108 | Metastatic Neur... | Biospecimen Col... Computed Tomogr... Lutetium Lu 177... Magnetic Resona... Triapine | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors | NCT05724108 | Metastatic Neur... | Biospecimen Col... Computed Tomogr... Lutetium Lu 177... Magnetic Resona... Triapine | 18 Years - | National Cancer Institute (NCI) | |
| Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors | NCT04665739 | Advanced Lung N... Functioning Lun... Locally Advance... Lung Neuroendoc... Lung Neuroendoc... Lung Neuroendoc... Metastatic Lung... Metastatic Lung... Non-Functioning... Recurrent Lung ... Unresectable Lu... Unresectable Lu... | Biospecimen Col... Computed Tomogr... Everolimus Fludeoxyglucose... Lutetium Lu 177... Positron Emissi... Single Photon E... | 18 Years - | National Cancer Institute (NCI) | |
| Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer | NCT05583708 | Merkel Cell Car... | Pembrolizumab Lutetium Lu 177... | 18 Years - | Weill Medical College of Cornell University | |
| 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry | NCT06395402 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | Lutetium Lu 177... | 18 Years - | University of Iowa | |
| Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors | NCT05687123 | Metastatic Panc... Pancreatic Neop... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Biospecimen Col... Computed Tomogr... Lutetium Lu 177... Magnetic Resona... Positron Emissi... Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer | NCT05583708 | Merkel Cell Car... | Pembrolizumab Lutetium Lu 177... | 18 Years - | Weill Medical College of Cornell University | |
| Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | NCT04106843 | Locally Advance... Locally Advance... Metastatic Adre... Metastatic Para... Metastatic Para... Pituitary Gland... Somatostatin Re... Stage III Thyro... Stage IV Thyroi... Stage IVA Thyro... Stage IVB Thyro... Stage IVC Thyro... Unresectable Ad... Unresectable Pa... | Lutetium Lu 177... | 18 Years - | M.D. Anderson Cancer Center | |
| Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | NCT04106843 | Locally Advance... Locally Advance... Metastatic Adre... Metastatic Para... Metastatic Para... Pituitary Gland... Somatostatin Re... Stage III Thyro... Stage IV Thyroi... Stage IVA Thyro... Stage IVB Thyro... Stage IVC Thyro... Unresectable Ad... Unresectable Pa... | Lutetium Lu 177... | 18 Years - | M.D. Anderson Cancer Center | |
| Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | NCT05691465 | Metastatic Pros... Metastatic Pros... Metastatic Pros... Stage IV Prosta... | Biospecimen Col... Computed Tomogr... Gallium Ga 68-D... Lutetium Lu 177... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer | NCT04529044 | Anatomic Stage ... Metastatic Brea... Prognostic Stag... Recurrent Breas... | Lutetium Lu 177... | 18 Years - 100 Years | OHSU Knight Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
